Biotech Alert! H.C. Wainwright Issued “Buy” Rating with $25 Price Target (+296.82% Upside Potential)

Breakout Alert: March 22, 2023 Biotech Alert! H.C. Wainwright Issued (MYNZ) “Buy” Rating with $25 Price Target (+296.82% Upside Potential) Hi 10XProTrader Member, This is Kevin Vander with “10XProTrader” delivering you your new premium alert for Thursday 2/23 - trading session is Mainz Biomed N.V. (Nasdaq: MYNZ). The Company has several bullish catalysts in the pipeline and is on the verge of Disrupting a multi-billion-do∙ll∙ar Colorectal Cancer Diagnostics Space with their recent Acquisition News, Mainz BioMed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program, and recent multiple Analysts coverage indicating +74.60%, +138.9%, +296.82% in upside potential. Bullish Catalyst - H.C. Wainwright Initiated Coverage of Mainz Biomed (Nasdaq: MYNZ) with a Buy rating and $25 Price Target [ (Representing +296.82% in Upside Potential) ]( Initiating with Buy Rating and $25 PT The price target at $25 implies over +296.82% upside to Wed. March 22, $6.30/share price and stands higher than the current $18.00 average price target for MYNZ on Wall Street. Symbol: MYNZ Company Name: Mainz Biomed N.V. Breakout Catalyst: (+++) Analysts $25.00 PT, $15 PT, $11 PT Analyst Coverage: H.C. Wainwright, Cantor Fitzgerald, JonesTrading About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomeds product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. Image by Scanz Level II via Mainz Biomed is a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, coming off of great news and recent multiple analysts coverage indicating +74.60%, +138.9%, +296.82% in upside potential. MYNZ CE-IVD Cleared Flagship Product ColoAlert is the FIRST DNA-based Screening Test for Colorectal Cancer in Europe Mainz Biomed ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up now! This leaves an open door for multiple near-term catalysts. Bullish Catalyst - Cantor Fitzgerald Initiated Coverage of Mainz Biomed (Nasdaq: MYNZ) with an OW Rating and $15 Price Target. [ (Representing +138.9% in Upside Potential) ]( Initiating with Buy Rating and $15 PT The price target at $15 implies over +138.9% upside to Weds. March 22nd, $6.30/share price but stands lower than the current$18 average price target for MYNZ on Wall Street. Mainz Biomed Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening Cantor Fitzgerald initiated its coverage on Cancer diagnostics test maker Mainz Biomed B.V. (Nasdaq: MYNZ) with an Overweight recommendation noting the company’s prospects in colorectal cancer screening. Mainz Biomed markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13BIL, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert. Commenting on Mainz Biomed’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” Bullish Catalyst - JonesTrading Initiated Coverage of Mainz Biomed (Nasdaq: MYNZ) with an Buy Rating and $11 Price Target. [ (Representing +74.60% in Upside Potential) ]( Initiating with Buy Rating and $11 PT The price target at $11 implies +74.60% upside to Weds. March 22nd, $6.30/share price but stands lower than the current $18 average price target for MYNZ on Wall Street. JonesTrading Initiated Feb. 9th, 2023 - Staking Its Claim In The Booming CRC Screening Market JonesTrading Research Report Highlights: "The future one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz Biomed, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." "Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)." "Valuation: Their $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany News Announced March 15, 2023 - Mainz Biomed (Nasdaq: MYNZ) has formed a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. “At Mainz, we are on a mission to save lives through the early detection of CRC – the third most common cancer globally – by increasing consumer access to affordable and reliable CRC screening tests like ColoAlert,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “We continue to build mutually beneficial partnerships with diagnostic labs such as Labor Staber, as we have found putting our PCR testing kits in the hands of highly professional laboratory networks to be a much more effective business model than the traditional methodology of operating testing at a single facility.” With more than 800 employees, including almost 100 medical specialists, biologists, chemists, and other academics from a wide variety of disciplines, Labor Staber offers a broad range of state-of-the-art medical diagnostics and services from a single source. Under the terms of this agreement, ColoAlert will now be marketed through Labor Staber’s extensive network of physicians and laboratories. “Our labs combine regional character and collegiality with the organizational competence of a Germany-wide active laboratory group,” said Dr. Thomas Kellerer, Head of Molecular Biology at Labor Staber. “We look forward to working with Mainz as we share the same passion – to improve patients’ lives by using the most advanced analysis methods and equipment, as well as the highest quality standards, in all of our medical diagnostics.” MYNZ Enters Commercial Partnerships for ColoAlert with Two Independent Laboratories News Announced Feb. 15, 2023 - Mainz Biomed (Nasdaq: MYNZ) has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain. Mainz Biomed markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Mainz Biomed (Nasdaq: MYNZ) Targets Multi-Billion-Do∙ll∙ar Sales Oppor∙tunity With Best-In-Class Cancer Screening Diagnostics Mainz Biomed is showing bullish momentum following several milestones reached, including strengthening its board and medical advisory team and expanding its best-in-class cancer diagnostics products deeper into international markets. Mainz Biomed (MYNZ) Has Demonstrated the Ability to Run Up Fast! While the recent bullish action is impressive, it's likely the potential precursor of more significant moves to come. Multiple Analysts on Wall Street released target price's on Mainz Biomed which I listed above. Mainz Biomed is currently hovering around approx. $6.30/share. If you're looking for a potential double or even a triple-digit-breakout, multiple analysts are bullish on Mainz Biomed. Now Turn Your Complete Attention to Mainz Biomed (Nasdaq: MYNZ) Our New Premium Nasdaq Biotech Breakout Alert for Thursday! Mainz Biomed is setting up to be a key player in the extremely Booming Billion-Do∙ll∙ar Biotech sector focusing on “early detection of cancer” using its Blockbuster Early Detection Test for Colorectal Cancer! MYNZ Has “10” Key Potential Breakout Catalysts That Provide A Very Bullish Outlook - Catalyst #1: Multiple Analysts Bullish on MYNZ, following latest updates and Blockbuster Acquisition News, Mainz BioMed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program. - Catalyst #2: H.C. Wainwright Initiated Coverage of MYNZ with a Buy rating and $25 Price Target. The price target at $25 implies over 296.82% upside to Weds. March 22nd, $6.30/share price and stands higher than the current $18.00 average price target for MYNZ on Wall Street. - Catalyst #3: Cantor Fitzgerald Initiated Coverage of MYNZ with an OW Rating and $15 Price Target. The price target at $15 implies over 138.9% upside to Weds. March 22nd, $6.30/share price but stands lower than the current $18 average price target for MYNZ on Wall Street. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13BIL, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert. Commenting on Mainz Biomed's valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” - Catalyst #4: JonesTrading Initiated Coverage of MYNZ with an Buy Rating and $11 Price Target. The price target at $11 implies 74.60% upside to Weds. March 22nd, $6.30/share price but stands lower than the current $18 average price target for MYNZ on Wall Street. We are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." - Catalyst #5: Mainz Biomed states that they will be seeking to obtain FDA approval for ColoAlert. The company just appointed Karen Richards as Vice President, Regulatory Affairs to lead the company through the FDA Approval Process. According to a recent press release from Mainz Biomed, the company CEO stated that Karen Richards brings specific expertise in shepherding diagnostic products through the U.S. regulatory process. ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. If Mainz Biomed gets FDA Approval for ColoAlert, who knows what could happen to the share price of Mainz. FDA Approval could potentially send the share price of MYNZ soaring. - Catalyst #6: Mainz Biomed is in the same space as Exact Sciences Corporation (EXAS) and over the last 5 years, their stock price has ran as much as +736.84% and currently has a market cap of over $11BIL which is around approx. 130x times the size of MYNZ. If Mainz Biomed could potentially grow its market cap equal to the current size of Exact Sciences Corporation (EXAS), that could mean a share price appreciate from around $10.39 to over $1,350 or the equivalent of a +12,893.26% potential gain. A move like that would be like turning $5,000 into over $600,000. - Catalyst #7: Mainz Biomed could potentially become the acquisition target of a much larger player in the space. Within the last year there have been multiple noteworthy acquisitions like Roche to acquire GenMark Diagnostics for $1.8BIL, DiaSorin to buy Luminex for $1.8BIL, Quidel Corporation (Nasdaq: QDEL) acquire Ortho Clinical Diagnostics (Nasdaq: OCDX) for $6BIL. There seems to be some deal making heating up in this space and if a larger player shows interest in (Nasdaq: MYNZ), there is no telling what could potentially happen to the share price. - Catalyst #8: Mainz Biomed (MYNZ) is listed on the NASDAQ exchange which allows pre-market trading. If there is any significant pre-market activity before the opening bell on Thursday morning, things could heat up very fast when buying attracts more buying as investors and traders look to position themselves ahead of the crowd. You need to have MYNZ pulled up on your screen and ready for some action if this thing looks like it's ready to break out to the upside. - Catalyst #9: Mainz Biomed is led by a very seasoned and experienced Management Team. The company's CEO, Guido Baechler has over 30 years of global experience leading public & private life science companies. Its CFO, William Caragol, has over 30 years of experience working with growth stage technology companies and is the Ex-Board Chair of Thermomedics, Inc., a privately held medical diagnostic equipment company. Karen Richards was recently appointed as Vice President of Regulatory Affairs, responsible for driving the development of new IVD products in compliance with regulatory requirements which is particularly important as she brings specific expertise in shepherding diagnostic products through the U.S. regulatory process, including the FDA. - Catalyst #10: The Company made key appointments to the management team and enhanced its Board of Directors and Medical Advisory Board: Darin Leigh, Chief Commercial Officer – Mr. Leigh is a former Abbott and Luminex executive with over 30 years of In Vitro Diagnostic (IVD) and life science experience. Amy Levin, Vice President of Regulatory Affairs – Ms. Levin brings to Mainz Biomed over 20 years of regulatory affairs experience. Previously, she worked as Director, Roche Molecular Diagnostics (RMD) International Regulatory Affairs. Jane Edwards, Vice President of Clinical Affairs – Ms. Edwards, has over 20 years of experience developing clinical trial strategies in diagnostics and medical devices. She was previously at L3 Healthcare, a full-service contract research organization, where she led clinical research and operations. Frank Krieg-Schneider, Vice President of Development – Mr. Krieg has over 25 years of experience in the diagnostics and life science industry, including leading various divisions within Qiagen’s diagnostic and life science practice, heading up research and development for Diagnostic Sample Preparation and later serving as Head of Global Strategic Alliances. Final Thoughts… Note, MYNZ is listed on the NASDAQ and has the ability to trade in after market trading hours and pre-market! Remember, any significant pre-market activity could potentially trigger a bu∙y∙ing frenzy at the opening bell! I'm urging you and all of my 10XProTrader community to add MYNZ to the very top of their watch list right now, and be ready Thursday morning at the opening bell! 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research Sources: 1): 2): 3): 4): 5): 6): 7): Leg∙al Entity Information: 10XProTrader is a website owned and operated by 10XPublishing, LLC., which is a DBA of 10XMedia, LLC. You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Help line: Customer service number is 1-800-803-4811 Mailing Address: Attn: Member Services | 10XMedia, LLC. 340 Royal Poinciana Way Suite 317-#409 Palm Beach, FL 33480 Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XMedia, LLC. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. This communication is a paid advertisement. 10XProTrader.coms is owned and operated by 10XMedia LLC, which is a Florida based Limited Liability Company and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Also, please note that we do not buy or sell in any securities that are profiled in our reports. We do not own shares of MYNZ and we will not have a position in MYNZ prior or during our reporting on the company. Please review the full disc∙laimer at [( for important information about this advertisement. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.